IDEAYA Biosciences近日宣布,其Ide397(一种潜在的首创Mat2a抑制剂)与Trodelvy®联合用于治疗Mtap缺失非小细胞肺癌的1/2期组合试验已完成首位患者入组。
这项临床试验标志着IDEAYA Biosciences在开发针对特定基因缺失患者群体的创新治疗方案方面迈出了重要一步。Ide397作为一种潜在的首创Mat2a抑制剂,与Trodelvy®的联合应用有望为Mtap缺失的非小细胞肺癌患者提供新的治疗选择。
IDEAYA Biosciences近日宣布,其Ide397(一种潜在的首创Mat2a抑制剂)与Trodelvy®联合用于治疗Mtap缺失非小细胞肺癌的1/2期组合试验已完成首位患者入组。
这项临床试验标志着IDEAYA Biosciences在开发针对特定基因缺失患者群体的创新治疗方案方面迈出了重要一步。Ide397作为一种潜在的首创Mat2a抑制剂,与Trodelvy®的联合应用有望为Mtap缺失的非小细胞肺癌患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.